Cargando…
Immunotherapeutic Agents for Intratumoral Immunotherapy
Immunotherapy using systemic immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cells has revolutionized cancer treatment, but it only benefits a subset of patients. Systemic immunotherapies cause severe autoimmune toxicities and cytokine storms. Immune-related adverse events (...
Autores principales: | Shyr, Chih-Rong, Liu, Lang-Chi, Chien, Hui-Shan, Huang, Chi-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674963/ https://www.ncbi.nlm.nih.gov/pubmed/38006049 http://dx.doi.org/10.3390/vaccines11111717 |
Ejemplares similares
-
Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases
por: Huang, Chi-Ping, et al.
Publicado: (2021) -
Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
por: Debele, Tilahun Ayane, et al.
Publicado: (2020) -
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
por: Aznar, M. Angela, et al.
Publicado: (2019) -
Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models
por: Huang, Chi-Ping, et al.
Publicado: (2020) -
Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)